COMPANY PROFILE // THE 014 REPORT
Compass Therapeutics, Inc.
CMPX (Nasdaq) · Formerly: Olivia Ventures, Inc.
Assembled from 2 government sources in 0.3 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2026-11-20 (last 24 months).
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Compass Therapeutics, Inc. is an SEC-registered operating company in biological products, (no diagnostic substances), incorporated in DE, based in Boston, MA; listed as CMPX (Nasdaq).[source] It reported revenue of $0 for the fiscal year ended 2025-12-31.[source] It has filed 53 documents with the SEC in the last 12 months; the latest is Form 8-K, filed 2026-11-20.[source] Its largest institutional holders on 13F filings are TANG CAPITAL MANAGEMENT LLC, ORBIMED ADVISORS LLC, MONTANOVA CAPITAL, LLC (as of 2026-06-30).[source] Seraphix flags 1 item from these records: 8-K Item 3.01 filed.[source]
- red0
- amber1
- info0
- TANG CAPITAL MANAGEMENT LLC$39.4M
- ORBIMED ADVISORS LLC$33.3M
- MONTANOVA CAPITAL, LLC$30.9M
- BlackRock, Inc.$24.7M
- STATE STREET CORP$21.8M
- ENAVATE SCIENCES GP, LLC$17.1M
- Vivo Capital, LLC$17.0M
- VANGUARD CAPITAL MANAGEMENT LLC$13.4M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Anderman Jonathan · General Counsel (Officer) · latest Form 4 2026-01-05 · filing · LinkedIn search
- Lerner Neil · Chief Accounting Officer (Officer) · latest Form 4 2026-01-05 · filing · LinkedIn search
- Prasad Arjun · Chief Commercial Officer (Officer) · latest Form 4 2026-01-05 · filing · LinkedIn search
- Schuetz Thomas J. · CHIEF EXECUTIVE OFFICER (Director,Officer) · latest Form 4 2026-02-10 · filing · LinkedIn search
- Shin Barry · CFO (Officer) · latest Form 4 2026-01-05 · filing · LinkedIn search
- Sirard Cynthia · Chief Medical Officer (Officer) · latest Form 4 2026-01-05 · filing · LinkedIn search
- Boylan James P · Director · latest Form 4 2026-01-05 · filing · LinkedIn search
- Chiniara Ellen · Director · latest Form 4 2026-01-05 · filing · LinkedIn search
- Ferneau Philip · Director · latest Form 4 2026-01-05 · filing · LinkedIn search
- GORDON CARL L · Director · latest Form 4 2026-01-05 · filing · LinkedIn search
- GRAY MARY ANN · Director · latest Form 4 2026-01-05 · filing · LinkedIn search
- LINDAHL RICHARD S · Director · latest Form 4 2026-01-05 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- GOODWIN PROCTER LLP · Exhibit 5.1 legal opinion, S-8 filed 2026-03-12
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 24 CLEAR, 2 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001738021 | source |
| EIN | 00-0000000 | source |
| Business address (SEC) | 80 GUEST STREET, BOSTON, MA, 02135 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 129 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 174 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2836 (biological products, (no diagnostic substances)): 183 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- AMGEN INC · 123 SEC filings in 12 months · 1 flag · $507.4M federal (possible match)
- Vir Biotechnology, Inc. · 117 SEC filings in 12 months · 1 flag · $65.9M federal (possible match)
- Vericel Corp · 109 SEC filings in 12 months · 1 flag · $37.3M federal (possible match)
- Coherus Oncology, Inc. · 53 SEC filings in 12 months · 3 flags · $11.8M federal (possible match)
- BIO-TECHNE Corp · 77 SEC filings in 12 months · 1 flag · $6.6M federal (possible match)
- Twist Bioscience Corp · 337 SEC filings in 12 months · 2 flags · $5.9M federal (possible match)
- Adaptive Biotechnologies Corp · 185 SEC filings in 12 months · 1 flag · $1.9M federal (possible match)
- AGENUS INC · 82 SEC filings in 12 months · 3 flags · $613K federal (possible match)
- REPLIGEN CORP · 89 SEC filings in 12 months · 1 flag · $457K federal (possible match)
- Revolution Medicines, Inc. · 171 SEC filings in 12 months · 2 flags · $15K federal (possible match)
- RECURSION PHARMACEUTICALS, INC. · 174 SEC filings in 12 months · 1 flag
- GILEAD SCIENCES, INC. · 173 SEC filings in 12 months
ADDRESS · ZIP CODE
Location context
At the same address (2)
- Aura Biosciences, Inc. · SEC registrant
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- ADARx Pharmaceuticals, Inc. · Carl L. Gordon, Ph.D., C.F.A.
- BlossomHill Therapeutics, Inc. · Carl L. Gordon, Ph.D., C.F.A.
- Electra Therapeutics, Inc. · Carl L. Gordon, Ph.D., C.F.A.
- Emergent BioSolutions Inc. · Richard S. Lindahl, M.B.A.
- Immunome Inc. · James P. Boylan, M.B.A.
- Keros Therapeutics, Inc. · Carl L. Gordon, Ph.D., C.F.A.
- Keros Therapeutics, Inc. · Mary Ann Gray, Ph.D.
- RAPT Therapeutics, Inc. · Mary Ann Gray, Ph.D.
- Scribe Therapeutics, Inc. · Carl L. Gordon, Ph.D., C.F.A.
- Zenas BioPharma, Inc. · James P. Boylan, M.B.A.
SEC registrants at the same address
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-20 filing 8-K items 3.01 · SEC EDGAR
- 2026-11-09 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-09 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-09-22 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-08-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-01 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-06-23 filing 8-K items 5.03,9.01 · SEC EDGAR
- 2026-06-11 filing 8-K items 5.07 · SEC EDGAR
- 2026-05-05 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-29 filing ARS · SEC EDGAR
- 2026-04-29 filing DEFA14A · SEC EDGAR
- 2026-04-29 filing Proxy statement · SEC EDGAR
- 2026-04-27 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-03-12 filing S-8 · SEC EDGAR
- 2026-03-05 filing Annual report (10-K) · SEC EDGAR
- 2026-03-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-01-07 filing EFFECT · SEC EDGAR
- 2026-01-06 filing 8-K items 2.02,8.01,9.01 · SEC EDGAR
- 2026-01-05 filing CORRESP · SEC EDGAR
- 2026-01-05 insider First Form 3/4/5 on record for Prasad Arjun (Chief Commercial Officer) · SEC Forms 3/4/5
- 2026-01-05 insider First Form 3/4/5 on record for Shin Barry (CFO) · SEC Forms 3/4/5
- 2026-01-05 insider First Form 3/4/5 on record for Sirard Cynthia (Chief Medical Officer) · SEC Forms 3/4/5
- 2026-01-05 insider First Form 3/4/5 on record for Boylan James P (Director) · SEC Forms 3/4/5
- 2026-01-05 insider First Form 3/4/5 on record for Chiniara Ellen (Director) · SEC Forms 3/4/5
- 2026-01-05 insider First Form 3/4/5 on record for Ferneau Philip (Director) · SEC Forms 3/4/5
- 2026-01-05 insider First Form 3/4/5 on record for GRAY MARY ANN (Director) · SEC Forms 3/4/5
- 2026-01-05 insider First Form 3/4/5 on record for LINDAHL RICHARD S (Director) · SEC Forms 3/4/5
- 2026-01-02 filing UPLOAD · SEC EDGAR
166 earlier entries
- 2025-12-31 filing DEL AM
- 2025-12-30 filing S-3
- 2025-11-05 filing Quarterly report (10-Q)
- 2025-11-05 filing 8-K items 2.02,9.01
- 2025-08-18 filing SCHEDULE 13D/A
- 2025-08-15 filing SCHEDULE 13D/A
- 2025-08-13 filing 8-K items 1.01,8.01,9.01
- 2025-08-13 filing 424B5
- 2025-08-12 filing 424B5
- 2025-08-11 filing Quarterly report (10-Q)
- 2025-08-11 filing 8-K items 2.02,7.01,9.01
- 2025-06-12 filing 8-K items 5.07
- 2025-05-27 insider First Form 3/4/5 on record for Schuetz Thomas J. (CHIEF EXECUTIVE OFFICER)
- 2025-05-08 filing Quarterly report (10-Q)
- 2025-05-08 filing 8-K items 2.02,9.01
- 2025-04-29 filing DEFA14A
- 2025-04-29 filing ARS
- 2025-04-29 filing Proxy statement
- 2025-04-11 filing SCHEDULE 13D/A
- 2025-04-11 insider First Form 3/4/5 on record for GORDON CARL L (Director)
- 2025-04-11 insider First Form 3/4/5 on record for ORBIMED ADVISORS LLC (Director,10% owner)
- 2025-04-11 insider First Form 3/4/5 on record for OrbiMed Capital GP VI LLC (Director,10% owner)
- 2025-04-11 insider First Form 3/4/5 on record for OrbiMed Genesis GP LLC (Director,10% owner)
- 2025-04-09 filing 144
- 2025-04-09 filing 144
- 2025-04-08 insider First Form 3/4/5 on record for Anderman Jonathan (General Counsel)
- 2025-04-08 insider First Form 3/4/5 on record for Lerner Neil (Chief Accounting Officer)
- 2025-04-01 filing 8-K items 7.01,8.01,9.01
- 2025-03-27 filing S-8
- 2025-02-27 filing Annual report (10-K)
- 2025-02-27 filing 8-K items 2.02,9.01
- 2025-01-08 filing 8-K items 2.02,8.01,9.01
- 2024-12-10 officer change 8-K items 5.02,7.01,9.01
- 2024-11-12 filing Quarterly report (10-Q)
- 2024-11-12 filing 8-K items 2.02,9.01
- 2024-09-06 filing EFFECT
- 2024-09-04 filing CORRESP
- 2024-09-03 filing UPLOAD
- 2024-08-30 filing S-3
- 2024-08-12 filing Quarterly report (10-Q)
- 2024-08-12 filing 8-K items 2.02,9.01
- 2024-06-17 filing 8-K items 5.07
- 2024-05-29 filing DEFA14A
- 2024-05-28 officer change 8-K items 5.02,7.01,9.01
- 2024-05-13 filing Quarterly report (10-Q)
- 2024-05-13 filing 8-K items 2.02,9.01
- 2024-04-29 filing ARS
- 2024-04-29 filing DEFA14A
- 2024-04-29 filing Proxy statement
- 2024-04-25 filing 8-K items 7.01,9.01
- 2024-03-22 filing SC 13D/A
- 2024-03-21 filing Annual report (10-K)
- 2024-03-21 filing 8-K items 2.02,9.01
- 2024-01-09 officer change 8-K items 5.02,8.01
- 2024-01-05 filing 8-K items 2.02,7.01,9.01
- 2023-11-09 filing Quarterly report (10-Q)
- 2023-11-09 filing 8-K items 2.02,9.01
- 2023-08-03 filing Quarterly report (10-Q)
- 2023-08-03 filing 8-K items 2.02,9.01
- 2023-06-15 filing 8-K items 5.07
- 2023-05-04 filing Quarterly report (10-Q)
- 2023-05-04 filing 8-K items 2.02,9.01
- 2023-04-27 filing ARS
- 2023-04-27 filing DEFA14A
- 2023-04-27 filing Proxy statement
- 2023-04-24 officer change 8-K items 5.02
- 2023-03-15 filing Annual report (10-K)
- 2023-03-10 filing 8-K items 7.01
- 2023-02-24 officer change 8-K items 5.02
- 2023-02-10 officer change 8-K items 5.02
- 2023-01-24 filing 424B3
- 2023-01-20 filing EFFECT
- 2023-01-19 filing 8-K items 8.01,9.01
- 2023-01-19 filing CORRESP
- 2023-01-17 filing CORRESP
- 2023-01-13 filing CORRESP
- 2022-12-07 filing UPLOAD
- 2022-12-02 filing S-3
- 2022-11-29 officer change 8-K items 5.02
- 2022-11-14 filing SC 13D
- 2022-11-10 filing SC 13D/A
- 2022-11-09 filing Quarterly report (10-Q)
- 2022-11-02 officer change 8-K items 1.01,3.02,5.02,9.01
- 2022-08-19 officer change 8-K items 5.02
- 2022-08-01 filing 424B5
- 2022-08-01 filing 8-K items 1.01,1.02,9.01
- 2022-08-01 filing Quarterly report (10-Q)
- 2022-05-31 filing 8-K items 5.07
- 2022-05-18 filing DEFA14A
- 2022-05-09 filing Quarterly report (10-Q)
- 2022-05-04 filing 8-K items 7.01,9.01
- 2022-04-28 filing Proxy statement
- 2022-04-26 officer change 8-K items 5.02,9.01
- 2022-03-18 filing Annual report (10-K)
- 2022-02-25 officer change 8-K items 5.02
- 2022-01-20 filing 8-K items 8.01,9.01
- 2021-12-21 officer change 8-K items 5.02
- 2021-12-15 filing 424B5
- 2021-12-15 filing 424B5
- 2021-11-12 filing Quarterly report (10-Q)
- 2021-11-09 filing SC 13D/A
- 2021-11-03 filing 8-K items 1.01,8.01,9.01
- 2021-11-03 filing 424B5
- 2021-11-01 filing CERT
- 2021-11-01 filing 424B5
- 2021-11-01 filing 8-A12B
- 2021-11-01 filing 8-K items 2.02,8.01,9.01
- 2021-10-08 filing 8-K items 8.01,9.01
- 2021-08-16 filing Quarterly report (10-Q)
- 2021-08-05 filing 8-K/A items 9.01
- 2021-07-20 filing EFFECT
- 2021-07-16 filing CORRESP
- 2021-07-15 filing UPLOAD
- 2021-07-14 filing SC 13D/A
- 2021-07-09 filing S-3
- 2021-06-30 officer change 8-K items 1.01,2.01,2.03,3.02,5.02,8.01,9.01
- 2021-06-04 filing 8-K items 5.07
- 2021-05-13 filing 8-K items 1.01,7.01,9.01
- 2021-04-30 filing 424B3
- 2021-04-30 filing Quarterly report (10-Q)
- 2021-04-29 filing Proxy statement
- 2021-04-19 officer change 8-K items 5.02,9.01
- 2021-03-11 filing 424B3
- 2021-03-08 filing EFFECT
- 2021-03-05 filing POS AM
- 2021-03-05 filing Annual report (10-K)
- 2021-01-14 filing S-8
- 2020-12-17 filing 8-K items 1.01,2.03
- 2020-11-13 filing RW
- 2020-11-12 filing CERT
- 2020-11-10 filing 8-A12B
- 2020-11-09 filing 424B3
- 2020-11-09 filing S-1/A
- 2020-11-09 filing Quarterly report (10-Q)
- 2020-10-19 filing Registration (S-1)
- 2020-09-25 filing EFFECT
- 2020-09-25 filing 424B3
- 2020-09-23 filing CORRESP
- 2020-09-23 filing DRS
- 2020-09-18 filing S-1/A
- 2020-09-15 officer change 8-K items 5.02,9.01
- 2020-08-14 filing UPLOAD
- 2020-08-13 filing Quarterly report (10-Q)
- 2020-08-11 filing Registration (S-1)
- 2020-08-11 filing UPLOAD
- 2020-07-31 filing CORRESP
- 2020-07-31 filing 8-K/A items 2.01
- 2020-07-17 filing UPLOAD
- 2020-07-01 filing D
- 2020-07-01 filing D
- 2020-06-29 filing SC 13D
- 2020-06-26 filing SC 13D
- 2020-06-26 filing SC 13D
- 2020-06-23 officer change 8-K items 1.01,2.01,3.02,4.01,5.01,5.02,5.03,5.06,9.01
- 2020-06-08 filing Annual report (10-K)
- 2020-06-08 name change Name changed from Olivia Ventures, Inc.
- 2020-05-28 filing SC 14F1/A
- 2020-05-27 filing SC 14F1
- 2020-02-14 filing Quarterly report (10-Q)
- 2019-11-13 filing Quarterly report (10-Q)
- 2019-08-13 filing Quarterly report (10-Q)
- 2019-07-01 filing Annual report (10-K)
- 2019-02-14 filing Quarterly report (10-Q)
- 2018-11-14 filing Quarterly report (10-Q)
- 2018-08-14 filing Quarterly report (10-Q)
- 2018-05-30 filing 10-12G
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-20 (within 7 days) 8-K filed: Item 3.01 delisting notice
- 2026-11-09 (within 30 days) 10-Q filed (FORM 10-Q)
- 2026-11-09 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-22 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-06 (older) 10-Q filed (FORM 10-Q)
- 2026-08-06 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-01 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-06-23 (older) 8-K filed: Item 5.03 charter or bylaw amendment; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:CMPX The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
5 possible matches held apart, matched by name only, not counted above; 2 records under a former name, shown apart.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1738021 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | CMPX / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| CUSIP | 20454B104 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001738021 | SEC EDGAR |
possible match: matched by name only, not merged (2)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| EPA FRS id | 110071062847 (COMPASS THERAPEUTICS) | name-exact: exact name match to 'Compass Therapeutics, Inc.' (no other entity shares the name) | EPA ECHO facilities |
| EPA FRS id | 110070354987 (COMPASS THERAPEUTICS LLC) | name-exact: exact name match to 'Compass Therapeutics, Inc.' (no other entity shares the name) | EPA ECHO facilities |
former name (shown apart, not merged) (2)
- former nameOlivia Ventures LLC · City licences
- former nameOLIVIA VENTURES, LLC · New York corporations
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $0 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerIncludingAssessedTax | as filed | 2026-11-21 11:43 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$66,489,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-21 11:43 UTC | Report an error |
| Total assets (at 2025-12-31) | $219,588,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-21 11:43 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $196,791,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-21 11:43 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $30,643,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-21 11:43 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-20 | SEC EDGAR company profile | as filed | 2026-11-21 11:43 UTC | Report an error |
| SIC industry | 2836 Biological Products, (No Diagnostic Substances) | 2026-11-20 | SEC EDGAR company profile | as filed | 2026-11-21 11:43 UTC | Report an error |
| State of incorporation | DE | 2026-11-20 | SEC EDGAR company profile | as filed | 2026-11-21 11:43 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-20 | SEC EDGAR company profile | as filed | 2026-11-21 11:43 UTC | Report an error |
| Business address | 80 GUEST STREET, BOSTON, MA, 02135 | 2026-11-20 | SEC EDGAR company profile | as filed | 2026-11-21 11:43 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-20 | SEC EDGAR company profile | as filed | 2026-11-21 11:43 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$49,143,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-21 11:43 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $25,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-21 11:43 UTC | Report an error |
| Operating lease liabilities (at 2025-09-30) | $9,829,000 | 2025-09-30 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-21 11:43 UTC | Report an error |
| Form D total offering amount (D filed 2020-07-01) | $70,000,000 | 2020-07-01 | D | as filed | 2026-11-21 11:43 UTC | Report an error |
| Form D total amount sold (D filed 2020-07-01) | $60,482,210 | 2020-07-01 | D | as filed | 2026-11-21 11:43 UTC | Report an error |
| Form D industry group | Other | 2020-07-01 | D | as filed | 2026-11-21 11:43 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2020-07-01 | D | as filed | 2026-11-21 11:43 UTC | Report an error |
| Form D date of first sale | 2020-06-19 | 2020-07-01 | D | as filed | 2026-11-21 11:43 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001171843-26-007258
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$27,171,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0001171843-26-007258 | 2026-11-21 11:43 UTC | Report an error |
| Cash and cash equivalents | $41,469,000 | at 2026-09-30 | 10-Q | 2026-11-09 | 0001171843-26-007258 | 2026-11-21 11:43 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-20 Filing 8-K filed: Item 3.01 delisting notice
- 2026-11-09 Filing 10-Q filed (FORM 10-Q)
- 2026-11-09 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-22 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-06 Filing 10-Q filed (FORM 10-Q)
- 2026-08-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-01 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-06-23 Filing 8-K filed: Item 5.03 charter or bylaw amendment; Item 9.01 exhibits
- 2026-06-11 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-05 Filing 10-Q filed (FORM 10-Q)
- 2026-05-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-29 Filing ARS filed
- 2026-04-29 Filing DEFA14A filed
- 2026-04-29 Filing DEF 14A filed
- 2026-04-27 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-03-12 Filing S-8 filed
- 2026-03-05 Filing 10-K filed (FORM 10-K)
- 2026-03-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-01-07 Filing EFFECT filed
- 2026-01-06 Filing 8-K filed: Item 2.02 results of operations; Item 8.01 other event; Item 9.01 exhibits
- 2026-01-05 Filing CORRESP filed
- 2026-01-02 Filing UPLOAD filed
- 2025-12-31 Filing DEL AM filed
- 2025-12-30 Filing S-3 filed
- 2025-11-05 Filing 10-Q filed (FORM 10-Q)
8-K item text, as filed (excerpts)
- 2026-11-20 8-K Item 3.01, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Transfer of Listing On November 19, 2026, Compass Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on The Nasdaq Capital… the 8-K · retrieved 2026-11-21 11:43 UTC - 2026-11-09 8-K Item 2.02, Results of Operations and Financial Condition
On November 9, 2026, Compass Therapeutics, Inc. issued a press release announcing financial results for the quarter and nine months ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. the 8-K · retrieved 2026-11-21 11:43 UTC - 2026-09-22 8-K Item 7.01, Regulation FD Disclosure
On September 22, 2026, Compass Therapeutics, Inc. (the “Company”) issued a press release announcing regulatory feedback from the FDA relating to tovecimig in patients with biliary tract cancer (“BTC”). A copy of the full press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information contained in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly… the 8-K · retrieved 2026-11-21 11:43 UTC - 2026-08-06 8-K Item 2.02, Results of Operations and Financial Condition
On August 6, 2026, Compass Therapeutics, Inc. issued a press release announcing financial results for the quarter and six months ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. the 8-K · retrieved 2026-11-21 11:43 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCOMPASS THERAPEUTICS · exact name match to 'Compass Therapeutics, Inc.' (no other entity shares the name) · sx:epa:110071062847 Compare
- possible matchCOMPASS THERAPEUTICS LLC · exact name match to 'Compass Therapeutics, Inc.' (no other entity shares the name) · sx:epa:110070354987 Compare
EPA RCRA hazardous waste (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCOMPASS THERAPEUTICS · exact name match to 'Compass Therapeutics, Inc.' (no other entity shares the name) · sx:rcra:MAR000592972 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | TANG CAPITAL MANAGEMENT LLC | $39,399,813 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:43 UTC | Report an error |
| 2 | ORBIMED ADVISORS LLC | $33,331,787 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:43 UTC | Report an error |
| 3 | MONTANOVA CAPITAL, LLC | $30,881,538 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:43 UTC | Report an error |
| 4 | BlackRock, Inc. | $24,707,100 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:43 UTC | Report an error |
| 5 | STATE STREET CORP | $21,798,500 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:43 UTC | Report an error |
| 6 | ENAVATE SCIENCES GP, LLC | $17,056,049 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:43 UTC | Report an error |
| 7 | Vivo Capital, LLC | $16,987,961 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:43 UTC | Report an error |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | $13,400,133 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:43 UTC | Report an error |
| 9 | Palo Alto Investors LP | $12,771,670 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:43 UTC | Report an error |
| 10 | MILLENNIUM MANAGEMENT LLC | $10,322,011 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:43 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
2 state and city records carry this company's exact name, from 1 source. Possible matches only.
ClinicalTrials.gov (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchCompass Therapeutics · exact name match to 'Compass Therapeutics, Inc.' (no other entity shares the name) · sx:ctgov:h45258fb9edd7dd12 Compare
- possible matchCompass Therapeutics, Inc · exact legal name · sx:ctgov:h2cf1fad8b6eb12ec Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1738021.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001738021. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.